Immunotherapy in Advanced Lung Cancer.

Area of Science:

• Oncology
• Immunotherapy

Background:

• Platinum-based chemotherapy was historically the standard for metastatic lung cancer.
• Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 pathways have shown efficacy in advanced non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC).

Purpose of the Study:

• To review the established role and integration of immune checkpoint inhibitors in the treatment of advanced NSCLC and ES-SCLC.
• To highlight the ongoing need for predictive biomarkers in immunotherapy for lung cancer.

Main Methods:

• Review of large-scale randomized clinical trials evaluating ICIs in NSCLC and ES-SCLC.
• Analysis of treatment guidelines and regulatory approvals for ICIs in lung cancer.

Main Results:

• Single-agent PD-1/PD-L1 inhibitors and combination therapy with platinum-based chemotherapy are now standard for advanced NSCLC.
• Two anti-PD-1/PD-L1 agents combined with chemotherapy are approved for frontline treatment of ES-SCLC.

Conclusions:

• Immunotherapy has significantly advanced lung cancer treatment paradigms.
• Development of reliable biomarkers is crucial for optimizing patient selection for ICI therapy.